Investor Alert: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Esperion Therapeutics, In...
January 22 2016 - 8:00PM
Business Wire
Khang & Khang LLP (the “Firm”) announces that a class action
lawsuit has been filed against Esperion Therapeutics, Inc.
(“Esperion” or the “Company”) (Nasdaq: ESPR). Investors who
purchased or otherwise acquired shares between August 18, 2015 and
September 28, 2015, inclusive (the “Class Period”) are encouraged
to contact the Firm prior to the March 14, 2016 lead plaintiff
motion deadline.
If you purchased shares of Esperion during the Class Period,
please contact Joon M. Khang, Esquire, of Khang & Khang, 18101
Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949)
419-3834, or by email at joon@khanglaw.com.
There has been no class certification in this case. Until
certification occurs, you are not represented by an attorney. You
may choose to take no action and remain a passive class member.
According to the complaint, the Company had no clear path to
approval for ETC-1002, the Company’s lead product candidate
designed to lower LDL-cholesterol levels. In addition, the FDA had
encouraged the Company to initiate a cardiovascular outcomes trial
(“CVOT”) and that completion of a CVOT could be necessary prior to
approval of ETC-1002.
If you purchased shares of Esperion during the Class Period, you
have until March 14, 2016 to ask the Court to appoint you as lead
plaintiff. If you wish to learn more about this lawsuit,
or if you have any questions concerning this notice or your rights,
please contact Joon M. Khang, a prominent litigator for almost two
decades, by telephone: (949) 419-3834, or by email at
joon@khanglaw.com.
This press release may constitute Attorney Advertising in some
jurisdictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160122005962/en/
KHANG & KHANG LLPJoon M. Khang, Esq.Telephone:
949-419-3834Facsimile: 949-225-4474joon@khanglaw.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024